Introduction
============

Colorectal cancer (CRC) is the second most common cause of cancer-associated mortality worldwide. Overall, \~50% of patients diagnosed with CRC succumb to the disease, due to complications associated with distant metastasis ([@b1-ol-08-05-2069]). The incidence of CRC in China has increased over recent years, particularly in the more developed areas ([@b2-ol-08-05-2069]). The tumor-host interaction at the invasive margin of CRC is a crucial interface where tumor progression and tumor cell dissemination ensue ([@b3-ol-08-05-2069]). Epithelial-mesenchymal transition (EMT), a dynamic process of colorectal carcinoma cell dedifferentiation, occurs at the invasive tumor front ([@b4-ol-08-05-2069]). The biological behavior of cancer is considered to be more accurately reflected by the histologic features present at the invasive front rather than those observed at the tumor center.

β-catenin is a component of the Wingless/Wnt signaling pathway. Dysfunction of the Wnt signaling pathway is important in colorectal carcinogenesis and results in the nuclear accumulation of β-catenin ([@b5-ol-08-05-2069]). Membranous beta-catenin forms a complex with E-cadherin, a critical mediator of cell-cell adhesion, and is responsible for the maintenance of cell polarity ([@b6-ol-08-05-2069]). The membranous expression of beta-catenin and E-cadherin characterizes the epithelial phenotype whereas the loss of this membranous expression is indicative of a switch toward a more mesenchymal phenotype. The nuclear translocation of β-catenin induces EMT and pro-invasive gene expression ([@b7-ol-08-05-2069]). Therefore, the differential intracellular distribution of β-catenin exerts a marked impact on the phenotype and behavior of tumor cells ([@b8-ol-08-05-2069]).

In the present study, the expression of the EMT-associated marker, β-catenin at the tumor invasive front and tumor center was investigated using immunohistochemical (IHC) analysis, and the correlations among β-catenin differential expression patterns, and clinicopathological characteristics and prognosis in CRC cases were determined.

Materials and methods
=====================

Patients and specimens
----------------------

A total of 181 CRC tissue samples were obtained from patients diagnosed with CRC (as determined by histopathological evaluation) and subjected to surgical resection at the First Hospital of China Medical University (Shenyang, China) between 2000 and 2001. None of the patients had been treated with preoperative chemotherapy or radiation. Two senior pathologists reviewed the tissue sections from all of the cases. Tumor histological classification was assessed according to the World Health Organization criteria ([@b9-ol-08-05-2069]) and classified using the seventh edition of the tumor, node, metastasis (TNM) staging manual produced by the International Union Against Cancer/American Joint Committee on Cancer (2010) ([@b10-ol-08-05-2069]). All patients were followed up via telephone enquiry or questionnaire. The follow-up time ranged between 1.5 and 71 months (median, 51 months). The Ethics Committee of China Medical University approved the use of tissue samples in this study. Written informed consent was obtained from all of the patients.

Antibodies and reagents
-----------------------

The primary antibodies used were monoclonal rabbit anti-human β-catenin (Abcam, Cambridge, UK).

Immunohistochemistry
--------------------

Formalin-fixed, paraffin-embedded sections (4-μm thick) were prepared from the CRC samples. The tissue sections were deparaffinized and rehydrated via sequential washing with xylene, graded ethanol and phosphate-buffered saline (PBS). Following deparaffinization and rehydration, the tissue sections were subjected to high temperature-induced epitope retrieval by briefly steaming in target retrieval solution (10 mM citrate buffer; pH 6.0; (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). Subsequently, the sections were treated with normal goat serum blocking solution (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) and then incubated with β-catenin primary antibody (dilution, 1:500) overnight at 4°C. Antibody binding was detected using an SP reagent kit (Zhongshan Chemical, Beijing, China) following the manufacturer's instructions. PBS replaced the primary antibody in the negative control and samples that were known to express β-catenin served as the positive controls. All sections were counterstained with hematoxylin, dehydrated and mounted.

Evaluation of staining
----------------------

The degree of IHC staining in the tissue sections was scored independently by two pathologists who were blinded to the clinical and pathological data. Staining intensity was graded using a scale of 0--3 as follows: 0, No staining; 1, weak staining; 2, moderate staining; and 3, strong staining ([@b11-ol-08-05-2069]). The extent of staining was graded on a scale as follows: 0, ≤5%; 1, 6--25%; 2, 26--50%; 3, 51--75%; or 4, 76--100% according to the percentage of the section exhibiting positive staining, relative to the entire carcinoma-involved area ([@b12-ol-08-05-2069],[@b13-ol-08-05-2069]). The intensity and extent scores were multiplied to generate the immunoreactivity score (IS; range, 0--12) for each case ([@b12-ol-08-05-2069],[@b13-ol-08-05-2069]). β-catenin immunoreactivity was separately analyzed for the tumor center and the tumor invasive front. Specimens were rescored if there were discrepancies in the IS obtained by the two pathologists, until a consensus was reached. Membranous expression of β-catenin was classified as preserved when \>80% of the cell membrane was stained; otherwise, the sample was classified as exhibiting reduced expression ([@b14-ol-08-05-2069]). High cytoplasmic and nuclear β-catenin expression grades were defined as \>50% reactivity of the tumor cells ([@b15-ol-08-05-2069]).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). The paired-samples t-test was used to compare the differential β-catenin expression levels between the tumor center and the tumor invasive front. The statistical significance of the associations between β-catenin expression levels and the patient clinicopathological parameters was assessed using χ^2^ tests. Kaplan-Meier survival curves were plotted to analyze the distribution of CRC-specific survival times and intergroup differences were determined using the log-rank test. A multivariate Cox regression model through a stepwise selection procedure was applied to examine the independence of the significant factors identified in the univariate analysis. Cox proportional hazards regression was used to calculate the mortality hazard ratios according to various clinicopathological features and protein markers. Two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Expression of β-catenin in CRC
------------------------------

β-catenin protein expression was evaluated in the CRC sections via IHC analysis. As shown in [Fig. 1](#f1-ol-08-05-2069){ref-type="fig"}, β-catenin staining was observed predominantly at the cell membrane, and marginally in the cell cytoplasm and nucleus. Membranous β-catenin expression was identified to be significantly higher in the tumor center than at the tumor invasive front (IS: 5.36±3.812 versus 0.42±1.252, respectively; P\<0.001). However, reduced membranous β-catenin expression levels in the tumor center were identified in 107 (59.1%) of the 181 patients. Nuclear β-catenin expression levels were significantly lower at the tumor center than at the tumor invasive front (IS: 0.05±0.303 versus 2.18±3.917, respectively; P\<0.001) as shown in [Fig. 2](#f2-ol-08-05-2069){ref-type="fig"} and [Table I](#tI-ol-08-05-2069){ref-type="table"}. High nuclear β-catenin expression levels at the tumor invasive front were observed in 30 (16.6%) of the 181 patients.

Correlation between β-catenin expression levels and the clinicopathological characteristics of CRC
--------------------------------------------------------------------------------------------------

The reduced membranous β-catenin expression levels at the tumor center were identified to be significantly associated with the occurrence of lymph node metastasis (P=0.002) and the TNM stage (P=0.002). However, no associations between reduced membranous β-catenin expression levels and age/gender at diagnosis, tumor site or size, invasion depth, presence or absence of tumor deposits, histological differentiation, or lymphatic or venous invasion were evident. In addition, no statistically significant correlations between cytoplasmic or nuclear expression levels of β-catenin and the above-mentioned clinicopathological characteristics were observed ([Table II](#tII-ol-08-05-2069){ref-type="table"}).

At the tumor invasive front, the detection of high nuclear expression levels of β-catenin was significantly correlated with lymph node metastasis (P=0.016), the TNM stage (P=0.020) and histological differentiation (P=0.006), however, not with age/gender at diagnosis, tumor site or size, invasion depth, presence or absence of tumor deposits, or lymphatic or venous invasion. In addition, high cytoplasmic expression levels of β-catenin were significantly correlated with histological differentiation (P=0.001) and tumor site (P=0.004). No statistically significant association was observed between the presence of high cytoplasmic expression of β-catenin and age/gender at diagnosis, tumor size, invasion depth, lymph node metastasis, TNM stage, presence or absence of tumor deposits, or lymphatic or venous invasion. Furthermore, no statistically significant correlation was detected between the detection of reduced membranous expression levels of β-catenin and the above-mentioned clinicopathological characteristics ([Table III](#tIII-ol-08-05-2069){ref-type="table"}).

Survival analysis
-----------------

Patients with reduced membranous expression levels of β-catenin at the tumor center had significantly lower cancer-specific five-year survival rates (58.5%), compared with patients that exhibited preserved membranous expression of β-catenin at the tumor center (78.1%; log-rank, P=0.028; [Fig. 3A](#f3-ol-08-05-2069){ref-type="fig"}). The difference in cancer-specific survival rates between patients with high-grade nuclear expression of β-catenin (five-year survival rate, 52.6%) and low-grade nuclear expression of β-catenin (five-year survival rate, 70.1%) at the tumor invasive front was also identified to be statistically significant (log-rank test, P=0.020; [Fig. 3B](#f3-ol-08-05-2069){ref-type="fig"}).

Univariate analysis revealed that the T stage (P\<0.001), N stage (P\<0.001), TNM stage (P\<0.001), the presence of lymphatic invasion (P\<0.001), the presence of tumor deposits (P\<0.001), reduced membranous expression levels of β-catenin at the tumor center (P=0.028) and high-grade nuclear expression of β-catenin at the tumor invasive front (P=0.020) were significant prognostic factors. However, age, gender, tumor location and size, tumor differentiation and venous invasion were not significantly associated with patient survival ([Table IV](#tIV-ol-08-05-2069){ref-type="table"}).

Multivariate analysis using Cox regression analysis demonstrated that the TNM stage (P\<0.001), presence of tumor deposits (P=0.001) and lymph node metastasis (P=0.026) were independent prognostic factors in CRC patients ([Table IV](#tIV-ol-08-05-2069){ref-type="table"}). In addition, multivariate analysis revealed that β-catenin levels were not a significant prognostic factor.

Discussion
==========

Despite significant advancements in CRC diagnosis and treatment, the prognosis for patients with advanced CRC remains poor. EMT, the switch from the polarized epithelial cell phenotype to a migratory mesenchymal phenotype, is increasingly recognized as a central event during malignant tumor progression and metastasis ([@b16-ol-08-05-2069],[@b17-ol-08-05-2069]). β-catenin maintains cell-to-cell adhesion along with E-cadherin. However, β-catenin also acts as a transcription factor in the Wnt signal transduction pathway ([@b5-ol-08-05-2069]). The dual role of β-catenin in cadherin-mediated cell-cell adhesion and in Wnt signaling, where it is a key effector, renders β-catenin an ideal target for analyzing the molecular basis of EMT and malignant cancer formation. The accumulation and aberrant activation of β-catenin signaling, as well as the transcription of target genes (hypothesized to contribute to various stages in tumor development) result from mutations in the adenomatous polyposis coli protein that abolish its capacity to bind β-catenin or mutations in the β-catenin phosphorylation motif at the N-terminus. The target genes include predominant regulators of EMT, for example Slug ([@b18-ol-08-05-2069]), which inhibits E-cadherin transcription. The release of β-catenin from cell-cell junctions following the dismantling of cell-cell adhesions, which contain E-cadherin, during EMT and the consequent activation of β-catenin-mediated transactivation are also important in EMT regulation ([@b19-ol-08-05-2069]).

However, the prognostic significance of β-catenin expression levels in patients with CRC remains controversial. Certain studies have shown that nuclear β-catenin expression is associated with high tumor budding and a poor prognosis ([@b15-ol-08-05-2069],[@b20-ol-08-05-2069],[@b21-ol-08-05-2069]), however, other studies did not detect this association ([@b22-ol-08-05-2069]--[@b24-ol-08-05-2069]). Additionally, a recent study revealed that β-catenin overexpression was correlated with a favorable prognosis ([@b25-ol-08-05-2069]).

Therefore, in the present study, the expression levels of the EMT-associated marker, β-catenin were investigated at the tumor invasive front and in the tumor center of CRC tissue specimens. Long-term clinical follow-up of the CRC patients was conducted and a large number of cases were included in the study, thus, the results are considered to be meaningful.

The levels of β-catenin protein expression in serial paraffin-embedded sections obtained from 181 human CRC samples were examined using IHC staining. The correlations between the β-catenin differential expression patterns and clinicopathological characteristics and prognosis were also assessed. The results showed that membranous β-catenin expression levels in the samples were significantly reduced at the tumor invasive front, compared with in the tumor center; however, nuclear β-catenin expression levels were significantly increased at the tumor invasive front, compared with in the tumor center. The dynamic changes in the intracellular distribution of β-catenin and the changes in tumor cell phenotype revealed a process that is reminiscent of EMT. The presence of reduced membranous expression levels of β-catenin at the tumor center was significantly associated with lymph node metastasis and the TNM stage. At the tumor invasive front, high-grade nuclear expression of β-catenin was significantly correlated with lymph node metastasis, TNM stage and histological differentiation.

Further analysis demonstrated that patients with reduced membranous expression levels of β-catenin had significantly lower cancer-specific five-year survival rates, compared with those patients exhibiting preserved membranous expression of β-catenin at the tumor center. The five-year survival rate of patients with high-grade nuclear β-catenin expression was significantly lower than that of patients with low-grade nuclear expression of β-catenin at the tumor invasive front. However, this did not persist as an independent prognostic factor following Cox multivariate analysis. The undifferentiated tumor cells at the tumor invasive front may undergo β-catenin-mediated EMT, which may result in the dissemination of tumor cells, and subsequently induce tumor invasion and metastasis.

In conclusion, the results of the present study indicate that changes in β-catenin expression levels are associated with aggressive morphological features, EMT and a poor prognosis in patients with CRC. IHC staining of β-catenin is considered to be a useful marker to predict the prognosis in CRC. However, large, well-designed prospective studies are required to further investigate the accurate prognostic significance of β-catenin.
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![Immunohistochemical staining of β-catenin in colorectal cancer samples. (A) β-catenin membranous expression. (B) β-catenin cytoplasmic expression. (C) β-catenin nuclear expression.](OL-08-05-2069-g00){#f1-ol-08-05-2069}

![Immunohistochemical staining demonstrating differential β-catenin expression levels at the tumor center and at the tumor invasive front. (A) Overview picture demonstrating both the tumor center and the tumor invasive front. The red arrows indicate tumor budding and nuclear β-catenin expression. (magnification, ×200). (B) At the tumor center, β-catenin expression was predominant at the cell membrane. (C) At the tumor invasive front, the red arrows indicate that the isolated single tumor cells or the small clusters of tumor cells (tumor budding) had scattered from the primary mass with marked nuclear β-catenin accumulation (epithelial-mesenchymal transition phenotype; magnification, ×400).](OL-08-05-2069-g01){#f2-ol-08-05-2069}

![Kaplan-Meier survival analysis. (A) β-catenin membranous expression at the tumor center; preserved membranous expression vs. reduced membranous expression (P=0.028). (B) β-catenin nuclear expression at the tumor invasive front; low vs. high expression levels (P=0.020).](OL-08-05-2069-g02){#f3-ol-08-05-2069}

###### 

Paired sample comparison (t-test) of β-catenin expression levels between the tumor center and tumor invasive front.

                         Immunoreactivity score                
  ---------------------- ------------------------ ------------ ---------
  Membranous β-catenin                                         
   Tumor center          181                      5.36±3.812   \<0.001
   Tumor front           181                      0.42±1.252   
  Nuclear β-catenin                                            
   Tumor center          181                      0.05±0.303   \<0.001
   Tumor front           181                      2.18±3.917   

P\<0.05 indicates a significant difference. SD, standard deviation.

###### 

β-catenin expression levels at the tumor center in association with patient clinicopathological variables.

                          Membranous expresssion levels   Cytoplasmic expression levels   Nuclear expression levels                                                         
  ----------------- ----- ------------------------------- ------------------------------- ---------------------------------------------------- ----- ---- ------- ----- --- -------
  Age (years)                                                                                                                                                               
   ≤60              65    21                              44                              0.079                                                47    18   0.248   62    3   0.255
   \>60             116   53                              63                                                                                   92    24           114   2   
  Gender                                                                                                                                                                    
   Male             105   43                              62                              0.982                                                82    23   0.626   103   2   0.408
   Female           76    31                              45                                                                                   57    19           73    3   
  Tumor size (cm)                                                                                                                                                           
   ≤5               94    40                              54                              0.635                                                71    23   0.675   91    3   0.714
   \>5              87    34                              53                                                                                   68    19           85    2   
  Tumor site                                                                                                                                                                
   Colon            72    27                              45                              0.425                                                59    13   0.182   69    3   0.349
   Rectum           109   47                              62                                                                                   80    29           107   2   
  T stage                                                                                                                                                                   
   pT1--pT2         61    30                              31                              0.106                                                52    9    0.055   60    1   0.511
   pT3--pT4         120   44                              76                                                                                   87    33           116   4   
  N stage                                                                                                                                                                   
   pN0              108   54                              54                              0.002[a](#tfn2-ol-08-05-2069){ref-type="table-fn"}   88    20   0.069   104   4   0.347
   pN1--pN2         73    20                              53                                                                                   51    22           72    1   
  TNM stage                                                                                                                                                                 
   I--II            107   54                              53                              0.002[a](#tfn2-ol-08-05-2069){ref-type="table-fn"}   87    20   0.084   103   4   0.335
   III--IV          74    20                              54                                                                                   52    22           73    1   
  Tumor deposit                                                                                                                                                             
   Absent           152   65                              87                              0.239                                                117   35   0.897   147   5   0.322
   Present          29    9                               20                                                                                   22    7            29    0   
  Differentiation                                                                                                                                                           
   Well, mod        132   57                              75                              0.302                                                98    34   0.182   127   5   0.167
   Por, muc         49    17                              32                                                                                   41    8            49    0   
  Lymph invasion                                                                                                                                                            
   Negative         167   70                              97                              0.329                                                128   39   0.870   162   5   0.511
   Positive         14    4                               10                                                                                   11    3            14    0   
  Venous invasion                                                                                                                                                           
   Negative         178   73                              105                             0.789                                                136   42   0.337   173   5   0.768
   Positive         3     1                               2                                                                                    3     0                  3   0

Statistically significant (P\<0.05).

TNM, tumor, node, metastasis; Mod, moderately differentiated; muc, mucinous adenocarcinoma; por, poorly differentiated and undifferentiated.

###### 

β-catenin expression levels at the tumor invasive front in association with patient clinicopathological variables.

                          Membranous expression levels   Cytoplasmic expression levels   Nuclear expression levels                                                                              
  ----------------- ----- ------------------------------ ------------------------------- --------------------------- ----- ---- ---------------------------------------------------- ----- ---- ----------------------------------------------------
  Age (years)                                                                                                                                                                                   
   ≤60              65    52                             13                              0.151                       37    28   0.080                                                57    8    0.248
   \>60             116   102                            14                                                          81    35                                                        94    22   
  Gender                                                                                                                                                                                        
   Male             105   91                             14                              0.482                       66    39   0.438                                                90    15   0.330
   Female           76    63                             13                                                          52    24                                                        61    15   
  Tumor size (cm)                                                                                                                                                                               
   ≤5               94    83                             11                              0.207                       60    34   0.689                                                76    18   0.333
   \>5              87    71                             16                                                          58    29                                                        75    12   
  Tumor site                                                                                                                                                                                    
   Colon            72    58                             14                              0.165                       56    16   0.004[a](#tfn4-ol-08-05-2069){ref-type="table-fn"}   62    10   0.430
   Rectum           109   96                             13                                                          62    47                                                        89    20   
  T stage                                                                                                                                                                                       
   pT1--pT2         61    54                             7                               0.354                       40    21   0.939                                                54    7    0.188
   pT3--pT4         120   100                            20                                                          78    42                                                        97    23   
  N stage                                                                                                                                                                                       
   pN0              108   91                             17                              0.705                       73    35   0.410                                                96    12   0.016[a](#tfn4-ol-08-05-2069){ref-type="table-fn"}
   pN1--pN2         73    63                             10                                                          45    28                                                        55    18   
  TNM stage                                                                                                                                                                                     
   I--II            107   90                             17                              0.659                       72    35   0.476                                                95    12   0.020[a](#tfn4-ol-08-05-2069){ref-type="table-fn"}
   III--IV          74    64                             10                                                          46    28                                                        56    18   
  Tumor deposit                                                                                                                                                                                 
   Absent           152   130                            22                              0.701                       99    53   0.968                                                129   23   0.232
   Present          29    24                             5                                                           19    10                                                        22    7    
  Differentiation                                                                                                                                                                               
   Well, mod        132   109                            23                              0.120                       77    55   0.001[a](#tfn4-ol-08-05-2069){ref-type="table-fn"}   104   28   0.006[a](#tfn4-ol-08-05-2069){ref-type="table-fn"}
   Por, muc         49    45                             4                                                           41    8                                                         47    2    
  Lymph invasion                                                                                                                                                                                
   Negative         167   143                            24                              0.476                       110   57   0.510                                                139   28   0.811
   Positive         14    11                             3                                                           8     6                                                         12    2    
  Venous invasion                                                                                                                                                                               
   Negative         178   151                            27                              0.465                       116   62   0.957                                                148   30   0.436
   Positive         3     3                              0                                                           2     1                                                         3     0    

Statistically significant (P\<0.05).

TNM, tumor, node, metastasis; Mod, moderately differentiated; muc, mucinous adenocarcinoma; por, poorly differentiated and undifferentiated.

###### 

Univariate and multivariate analyses of survival rates in colorectal cancer patients.

                                            Univariate analysis   Multivariate analysis                                                          
  ----------------------------------- ----- --------------------- ------------------------------------------------------ -------- -------------- ------------------------------------------------------
  Age (years)                                                                                                                                    
   ≤60                                65    69.7                  0.254                                                                          
   \>60                               116   66.0                                                                                                 
  Gender                                                                                                                                         
   Male                               105   69.9                  0.151                                                                          
   Female                             76    64.0                                                                                                 
  Tumor size (cm)                                                                                                                                
   ≤5                                 94    64.2                  0.814                                                                          
   \>5                                87    70.6                                                                                                 
  Tumor site                                                                                                                                     
   Colon                              72    65.2                  0.266                                                                          
   Rectum                             109   68.3                                                                                                 
  T stage                                                                                                                                        
   pT1--pT2                           61    85.7                  \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}                           
   pT3--pT4                           120   58.5                                                                                                 
  N stage                                                                                                                                        
   pN0                                108   92.5                  \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}   10.729   1.336--86.14   0.026[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}
   pN1--pN2                           73    32.3                                                                                                 
  TNM stage                                                                                                                                      
   I--II                              107   93.4                  \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}   0.009    0.001--0.082   \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}
   III--IV                            74    31.8                                                                                                 
  Tumor deposit                                                                                                                                  
   Absent                             152   76.8                  \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}   0.368    0.208--0.651   0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}
   Present                            29    17.2                                                                                                 
  Differentiation                                                                                                                                
   Well, mod                          132   68.7                  0.984                                                                          
   Por, muc                           49    62.8                                                                                                 
  Lymph invasion                                                                                                                                 
   Negative                           167   70.1                  \<0.001[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}                           
   Positive                           14    35.7                                                                                                 
  Venous invasion                                                                                                                                
   Negative                           178   67.9                  0.086                                                                          
   Positive                           3     33.3                                                                                                 
  Tumor center membranous β-catenin                                                                                                              
   Preserved                          74    78.1                  0.028[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}     1.132    0.627--2.046   0.681
   Reduced                            107   58.5                                                                                                 
  Tumor front nuclear β-catenin                                                                                                                  
   Low-grade                          151   70.1                  0.020[a](#tfn6-ol-08-05-2069){ref-type="table-fn"}     0.708    0.384--1.705   0.268
   High-grade                         30    52.6                                                                                                 

Statistically significant (P\<0.05). The forward stepwise Cox regression approach was performed for the statistical analyses and the non-significant variables are not presented in the final table.

CI, confidence interval; HR, hazard ratio; TNM, tumor, node, metastasis; mod, moderately differentiated; muc, mucinous adenocarcinoma; por, poorly differentiated and undifferentiated.
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